Achieve Life Sciences, Inc.
NASDAQ:ACHV · NASDAQ Capital Market
-$0.38 today
Vol 4.48M · Avg 1.44M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:ACHV · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$52.0M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.12, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $228.0K -0.4% | $229.0K | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$228.0K +0.4% | -$229.0K | $0 | $0 | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $23.0M +0.6% | $22.8M +44.3% | $15.8M -47.4% | $30.1M +25.5% | $24.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $31.9M +96.1% | $16.3M +42.1% | $11.4M +6.7% | $10.7M +17.5% | $9.1M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $54.7M +40.7% | $38.8M +42.5% | $27.3M -33.2% | $40.8M +23.3% | $33.1M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $228.0K -0.4% | $229.0K +0.4% | $228.0K -3.4% | $236.0K -5.6% | $250.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$53.6M -43.2% | -$37.4M -40.0% | -$26.7M +33.7% | -$40.3M -22.6% | -$32.9M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$54.9M -40.5% | -$39.1M -43.4% | -$27.3M +33.2% | -$40.8M -23.3% | -$33.1M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.5M -36.5% | $2.4M +185.6% | $825.0K +314.6% | $199.0K +1070.6% | $17.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $819.0K -62.4% | $2.2M -23.6% | $2.9M +59.5% | $1.8M | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $232.0K +130.6% | -$758.0K +70.4% | -$2.6M -65.5% | -$1.6M -2572.4% | -$58.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$54.6M -37.2% | -$39.8M -33.6% | -$29.8M +29.6% | -$42.4M -27.7% | -$33.2M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$54.6M -37.2% | -$39.8M -33.6% | -$29.8M +29.6% | -$42.4M -27.7% | -$33.2M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 -0.8% | -$1 +17.3% | -$2 +62.0% | -$4 +2.5% | -$4 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 -0.8% | -$1 +17.3% | -$2 +62.0% | -$4 +2.5% | -$4 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $43.6M +35.9% | $32.1M +61.8% | $19.8M +87.2% | $10.6M +30.5% | $8.1M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $43.6M +35.9% | $32.1M +61.8% | $19.8M +87.2% | $10.6M +30.5% | $8.1M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.29B
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$485.30M
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
$346.38M
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$344.52M
Entrada Therapeutics, Inc.
NASDAQ:TRDA
$266.50M
Voyager Therapeutics, Inc.
NASDAQ:VYGR
$223.26M
Sagimet Biosciences Inc.
NASDAQ:SGMT
$217.64M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$211.33M
Immuneering Corporation
NASDAQ:IMRX
$156.64M
Humacyte, Inc.
NASDAQ:HUMA
$154.02M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ACHV generate?
Achieve Life Sciences, Inc. (ACHV) reported $0.00 of revenue in fiscal 2025.
Is ACHV profitable?
Achieve Life Sciences, Inc. (ACHV) reported -$54,648,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.